8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


       Date of Report (Date of earliest event reported) September 4, 2007
                                                        -----------------

                             REPRO-MED SYSTEMS, INC.
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)


          NEW YORK                       0-12305                 13-3044880
- ----------------------------           ------------          -------------------
(State or other jurisdiction           (Commission             (IRS Employer
      of incorporation)                File Number)          Identification No.)


               24 Carpenter Road, Chester, New York            10918
             ----------------------------------------        ----------
             (Address of principal executive offices)        (Zip Code)


        Registrant's telephone number, including area code (914) 469-2042
                                                           --------------

                                 not applicable
         --------------------------------------------------------------
         (Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))



ITEM 8.01 OTHER EVENTS.

According to a guidance document from Medicare's Region B contracting agent, the
Freedom60, manufactured by Repro-Med Systems (REPR.OB) dba RMS Medical Products
in Chester New York, is the only infusion pump to be reimbursed for use with
subcutaneous immune globulin. A copy of the press release is attached as Exhibit
99.1. A copy of the guidance document is attached as Exhibit 99.2.


ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

Exhibit   Description
- -------   -----------

99.1      Press release dated September 4, 2007.

99.2      Guidance document from Medicare's Region B contracting agent.


                                   SIGNATURES

          Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                       REPRO-MED SYSTEMS, INC.
                                       (Registrant)


Date  September 4, 2007                By: /s/ Andrew I. Sealfon
      -----------------                    ---------------------
                                           Andrew I. Sealfon
                                           President and Chief Executive Officer

                                     - 2 -

EX-99

                                                                    EXHIBIT 99.1

              MEDICARE CLARIFICATION REIMBURSING THE FREEDOM60 WITH
                          SUBCUTANEOUS IMMUNE GLOBULIN

CHESTER, N.Y., September 4, 2007 -- According to a guidance document from
Medicare's Region B contracting agent, the Freedom60, manufactured by Repro-Med
Systems (REPR.OB) dba RMS Medical Products in Chester New York, is the only
infusion pump to be reimbursed for use with subcutaneous immune globulin.

"The Freedom 60 Syringe Infusion Pump is the only allowable pump to be billed
with the Subcutaneous Immune Globulin (SCIG)," states the guidance document
released in June 2007. This notification goes on to say, "All other pumps or
modifiers will result in a denial." The document may be viewed in its entirety
at:

http://www.adminastar.com/Providers/DMERC/MedicalReview/files/ClarificationonExt
ernalInfusionPumpswithSubcutaneous.pdf

Subcutaneous immune globulin is used to treat a medical condition called Primary
Immune deficiency (PI), usually considered to be genetic group of disorders
currently affecting an estimated 50,000 Americans. These disorders compromise
the immune system, leaving patients vulnerable to recurrent, life- threatening
infections. Immune globulin is a life-sustaining blood product that has become a
standard replacement therapy for most people diagnosed with PI, with nearly 70%
of PI patients receiving some form of IgG replacement therapy.

The Freedom60 Syringe Infusion Pump is the preferred system for the
administration of immune globulin due to its safe, controlled pressure and
ability to automatically adjust the flow rate to meet the needs of the patient.
This inherently safe design minimizes pain, swelling and other complications
caused by the use of conventional electric infusion devices. "The reality is
that not only does the Freedom60 have the most effective technology to
administer various medications at the lowest cost per dose, but for IgG, it is
the safest, it results in the least side effects, it is the lowest cost device
on the market, and it is the only product that is reimbursed by Medicare for
SCIG," commented Andy Sealfon, President of Repro- Med Systems. "Why would
anyone use something else?"

For many uses, the Freedom60 offers a portable, high quality, non- electric,
maintenance free delivery system for ambulatory, home and hospital use,
delivering precise infusion rates and uniform flow profiles that provide
consistent transfer of medication. The Freedom60 is a versatile, easy-to-use
lightweight mechanical pump providing a cost-effective alternative to expensive
electronic and disposable IV administration devices and may be used to deliver a
wide range of infusion products including antibiotics, pain control,
chemotherapy drugs, desferal, and cardiac drugs, among others.

Forward Looking Statements

Statements in this press release may contain "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995. All
statements, other than statements of historical facts, may be forward- looking
statements. These statements are based on management's current expectations and
are subject to uncertainty and changes in circumstances. These statements
involve risks and uncertainties that could cause actual results to differ
materially from those included in forward-looking statements due to a variety of
factors. More information about these factors can be found in Repro-Med's latest
Annual Report filed with Securities and Exchange Commission on Form 10-KSB. The
company undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.

Andy Sealfon
1-800-624-9600 x 307
RMS Medical Products
24 Carpenter Road
Chester, New York 10918                Visit our web site at:  www.Freedom60.com

EX-99

EXHIBIT 99.2